Natalie S Callander MD

Oncology•Madison, WI

Hematologic Oncology

Associate Professor, Medicine, University of Wisconsin Medical School

Join to View Full Profile

600 Highland AveMadison, WI 53792
Phone+1 608-265-1700
Fax+1 608-266-6020

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
NYU Grossman School of MedicineResidency, Internal Medicine, 1985 - 1988
Tufts University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1988 - Present
WI State Medical License 2004 - 2027
TX State Medical License 1995 - 2024
GA State Medical License 1989 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
ACTIVE_NOT_RECRUITING
PHASE3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Jul 28
ACTIVE_NOT_RECRUITING
PHASE3
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Jul 23
Completed
Phase 1
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Start of enrollment: 2022 Jan 05
COMPLETED
PHASE2
Roles: Contact
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Contact
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
RECRUITING
PHASE1, PHASE2
Roles: Contact
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 23
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and M...
Ajai Chari, Susan Bal, Sikander Ailawadhi, Amrita Krishnan, Krina K Patel
Clinical Lymphoma, Myeloma & Leukemia. 2025-09-01
2 citations
Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.
Smith Giri, Binod Dhakal, Natalie S Callander, Eva Medvedova, Kelly Godby
Blood. 2025-08-07
7 citations
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic
Journal of the National Comprehensive Cancer Network. 2025-05-01

Abstracts/Posters

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoi...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Natalie Scott Callander, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients$
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsAugust 29th, 2025
$Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients$
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsAugust 29th, 2025
$Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma$
Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaAugust 15th, 2025
Join now to see all